Dennis J Sholler1, Lauren Schoene1, Tory R Spindle1. 1. Behavioral Pharmacology Research Unit, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Abstract
PURPOSE OF REVIEW: Global policy changes have increased access to products containing cannabidiol (CBD), a primary constituent of hemp and cannabis. The CBD product industry has experienced tremendous growth, in part, because CBD is widely touted as an effective therapeutic for myriad health conditions. However, only 1 CBD product (Epidiolex®) has been approved by the U.S. Food and Drug Administration (FDA) to date. There is substantial interest among consumers and the medical and scientific communities regarding the therapeutic potential of CBD, including for novel indications that are not recognized by the FDA. The purpose of this review was to synthesize available evidence from clinical research regarding the efficacy of CBD as a therapeutic. RECENT FINDINGS: Human laboratory studies and clinical trials (e.g., randomized controlled trials and single-arm, open label trials) evaluating the efficacy of CBD as a therapeutic were identified for various medical conditions, including epilepsy, anxiety, pain/inflammation, schizophrenia, various substance use disorders, post-traumatic stress disorder, and others. There is clear evidence supporting the utility of CBD to treat epilepsy. For other health conditions reviewed, evidence was often mixed and/or there was a general lack of well-powered randomized, placebo-controlled studies to draw definitive conclusions. SUMMARY: Rigorous, controlled evidence for the therapeutic efficacy of CBD is lacking for many health conditions. Possible concerns with the use of CBD as a therapeutic include the potential for adverse effects (e.g., liver toxicity), drug-drug interactions, and lack of sufficient regulatory oversight of retail CBD products.
PURPOSE OF REVIEW: Global policy changes have increased access to products containing cannabidiol (CBD), a primary constituent of hemp and cannabis. The CBD product industry has experienced tremendous growth, in part, because CBD is widely touted as an effective therapeutic for myriad health conditions. However, only 1 CBD product (Epidiolex®) has been approved by the U.S. Food and Drug Administration (FDA) to date. There is substantial interest among consumers and the medical and scientific communities regarding the therapeutic potential of CBD, including for novel indications that are not recognized by the FDA. The purpose of this review was to synthesize available evidence from clinical research regarding the efficacy of CBD as a therapeutic. RECENT FINDINGS: Human laboratory studies and clinical trials (e.g., randomized controlled trials and single-arm, open label trials) evaluating the efficacy of CBD as a therapeutic were identified for various medical conditions, including epilepsy, anxiety, pain/inflammation, schizophrenia, various substance use disorders, post-traumatic stress disorder, and others. There is clear evidence supporting the utility of CBD to treat epilepsy. For other health conditions reviewed, evidence was often mixed and/or there was a general lack of well-powered randomized, placebo-controlled studies to draw definitive conclusions. SUMMARY: Rigorous, controlled evidence for the therapeutic efficacy of CBD is lacking for many health conditions. Possible concerns with the use of CBD as a therapeutic include the potential for adverse effects (e.g., liver toxicity), drug-drug interactions, and lack of sufficient regulatory oversight of retail CBD products.
Authors: Yasmin L Hurd; Sharron Spriggs; Julia Alishayev; Gary Winkel; Kristina Gurgov; Chris Kudrich; Anna M Oprescu; Edwin Salsitz Journal: Am J Psychiatry Date: 2019-05-21 Impact factor: 18.112
Authors: Mateus M Bergamaschi; Regina Helena Costa Queiroz; Marcos Hortes Nisihara Chagas; Danielle Chaves Gomes de Oliveira; Bruno Spinosa De Martinis; Flávio Kapczinski; João Quevedo; Rafael Roesler; Nadja Schröder; Antonio E Nardi; Rocio Martín-Santos; Jaime Eduardo Cecílio Hallak; Antonio Waldo Zuardi; José Alexandre S Crippa Journal: Neuropsychopharmacology Date: 2011-02-09 Impact factor: 7.853
Authors: Margaret Haney; Robert J Malcolm; Shanna Babalonis; Paul A Nuzzo; Ziva D Cooper; Gillinder Bedi; Kevin M Gray; Aimee McRae-Clark; Michelle R Lofwall; Steven Sparenborg; Sharon L Walsh Journal: Neuropsychopharmacology Date: 2015-12-28 Impact factor: 7.853
Authors: Khalid A Jadoon; Stuart H Ratcliffe; David A Barrett; E Louise Thomas; Colin Stott; Jimmy D Bell; Saoirse E O'Sullivan; Garry D Tan Journal: Diabetes Care Date: 2016-08-29 Impact factor: 19.112
Authors: Wanshan Feng; Chaolong Qin; Elena Cipolla; Jong Bong Lee; Atheer Zgair; Yenju Chu; Catherine A Ortori; Michael J Stocks; Cris S Constantinescu; David A Barrett; Peter M Fischer; Pavel Gershkovich Journal: Pharmaceutics Date: 2021-08-27 Impact factor: 6.525
Authors: Kieran Shay Struebin Abbotts; Taylor Russell Ewell; Hannah Michelle Butterklee; Matthew Charles Bomar; Natalie Akagi; Gregory P Dooley; Christopher Bell Journal: Nutrients Date: 2022-05-21 Impact factor: 6.706
Authors: Dennis J Sholler; Tory R Spindle; Edward J Cone; Elia Goffi; David Kuntz; John M Mitchell; Ruth E Winecker; George E Bigelow; Ronald R Flegel; Ryan Vandrey Journal: J Anal Toxicol Date: 2022-05-20 Impact factor: 3.220
Authors: José Diogo S Souza; Antonio W Zuardi; Francisco S Guimarães; Flávia de Lima Osório; Sonia Regina Loureiro; Alline Cristina Campos; Jaime E C Hallak; Rafael G Dos Santos; Isabella Lara Machado Silveira; Karina Pereira-Lima; Julia Cozar Pacheco; Juliana Mayumi Ushirohira; Rafael Rinaldi Ferreira; Karla Cristinne Mancini Costa; Davi Silveira Scomparin; Franciele Franco Scarante; Isabela Pires-Dos-Santos; Raphael Mechoulam; Flávio Kapczinski; Benedito A L Fonseca; Danillo L A Esposito; Maristela Haddad Andraus; José Alexandre S Crippa Journal: Front Pharmacol Date: 2022-10-03 Impact factor: 5.988
Authors: Ekaterina V Fedorova; Carolyn F Wong; Janna Ataiants; Ellen Iverson; Bridgid M Conn; Stephen E Lankenau Journal: Drug Alcohol Depend Date: 2021-02-22 Impact factor: 4.492